Undisclosed Oncology Program
Sarcomas and Prostate Cancer
Lead OptimizationEarly candidates; ongoing lead optimization
Key Facts
Indication
Sarcomas and Prostate Cancer
Phase
Lead Optimization
Status
Early candidates; ongoing lead optimization
Company
About Altay Therapeutics
Altay Therapeutics is a private, preclinical-stage biotech focused on unlocking transcription factors as therapeutic targets. The company's core technology is a therapeutic area-agnostic platform that identifies novel allosteric sites on transcription factors to design highly selective oral inhibitors. With its lead FSHD program expected to enter IND-enabling studies in 2025 and a STAT3 inhibitor in lead optimization, Altay is positioning itself as a leader in a challenging but high-potential drug discovery space, supported by grants and recognition from major pharmaceutical companies.
View full company profile